The final, formatted version of the article will be published soon.
REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1428584
This article is part of the Research Topic Mechanism Explorations of Enhancing Immunotherapeutic Sensitivity via Mediating Immune Infiltration and Programmed Cell Death in Solid Tumor Microenvironment View all articles
A Future Directions of Renal cell Carcinoma Treatment: Combination of Immune Checkpoint Inhibition and Carbon ion radiotherapy
Provisionally accepted
Zhouhang Zheng
1*
Tianci Yang
1
Yixuan Li
1
Pei Qu
2
Zhiang Shao
2*
Yuan Wang
2*
Wei Chang
1
Shahzad M. Umar
1*
Wei Wang
1*
Nan Ding
2*
Jufang Wang
2*- 1 Department of Urology, Lanzhou University Second Hospital, Lanzhou, China
- 2 Institute of Modern Physics, Chinese Academy of Sciences (CAS), Lanzhou, Gansu Province, China
Renal cell carcinoma (RCC) is considered radio-and chemo-resistant. Immune checkpoint inhibitors (ICIs) have demonstrated significant clinical efficacy in advanced RCC. However, the overall response rate of RCC to monotherapy remains limited. Given its immunomodulatory effects, a combination of radiotherapy (RT) with immunotherapy is increasingly used for cancer treatment. Heavy ion radiotherapy, specifically the carbon ion radiotherapy (CIRT), represents an innovative approach to cancer treatment, offering superior physical and biological effectiveness compared to conventional photon radiotherapy and exhibiting obvious advantages in cancer treatment. The combination of CIRT and immunotherapy showed robust effectiveness in preclinical studies of various tumors, thus holds promise for overcoming radiation resistance of RCC and enhancing therapeutic outcomes. Here, we provide a comprehensive review on the biophysical effects of CIRT, the efficacy of combination treatment and the underlying mechanisms involved in, as well as its therapeutic potential specifically within RCC.
Keywords: Renal cell carcinoma (RCC), Radiotherapy, Immunotherapy, Carbon ion radiotherapy, combination therapy
Received: 06 May 2024; Accepted: 05 Jul 2024.
Copyright: © 2024 Zheng, Yang, Li, Qu, Shao, Wang, Chang, Umar, Wang, Ding and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zhouhang Zheng, Department of Urology, Lanzhou University Second Hospital, Lanzhou, China
Zhiang Shao, Institute of Modern Physics, Chinese Academy of Sciences (CAS), Lanzhou, 730000, Gansu Province, China
Yuan Wang, Institute of Modern Physics, Chinese Academy of Sciences (CAS), Lanzhou, 730000, Gansu Province, China
Shahzad M. Umar, Department of Urology, Lanzhou University Second Hospital, Lanzhou, China
Wei Wang, Department of Urology, Lanzhou University Second Hospital, Lanzhou, China
Nan Ding, Institute of Modern Physics, Chinese Academy of Sciences (CAS), Lanzhou, 730000, Gansu Province, China
Jufang Wang, Institute of Modern Physics, Chinese Academy of Sciences (CAS), Lanzhou, 730000, Gansu Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.